Business Merck Reports Strong Q2 Growth Driven by Oncology and Animal Health; FDA Approves First Oral PCSK9 Inhibitor August 4, 2026 Merck & Co., Inc. delivered second-quarter 2026 results that exceeded Wall Street expectations, posting revenue of $16.6 billion and demonstrating continued strength across its oncology portfolio and animal health division.…
Health Replimune Resubmits Melanoma Drug After FDA Leadership Exodus May 29, 2026 Third Submission Follows Major Regulatory Changes Replimune Group will resubmit its biologics license application for melanoma therapy RP1 in the coming days. Replimune made the decision after significant leadership changes…